Research Program Members

Lawrence Afrin, MD
Professor

612-624-0123
afrinl@umn.edu

Chronic myeloproliferative neoplasms, especially the mast cell activation diseases and in particular the newly recognized mast cell activation syndrome; expertise in medical informatics.

Full bio

Mukta Arora, MD, MS
Associate Professor

612-624-0123
arora005@umn.edu

Development of novel strategies for preventing chronic GVHD and identification of risk factors

Full bio

Veronika Bachanova, MD, PhD
Associate Professor

612-624-0123
bach0173@umn.edu

Immune-based therapies for lymphoma and other related malignancies

Full bio

Nelli Bejanyan, MD
Assistant Professor

612-624-6982
nbejanya@umn.edu

Development of novel clinical trials for reducing the early complications of allogeneic HCT and limiting myeloid leukemia recurrence.

Full bio

Bruce Blazar, MD
Regents Professor

612-626-2734
blaza001@umn.edu

Regulation of the immune response after allogeneic HCT using murine model systems, development of immune-based therapies (e.g., use of Treg cells to modulate engraftment and GVHCO, and development of stem cell-based therapies for tissue repair after chemoradiotherapy.

Full bio

Claudio Brunstein, MD, PhD
Associate Professor

612-624-0123
bruns072@umn.edu

The application of unrelated cord blood transplantation in adults; clinical trials evaluating a) complement fragment 3a (C3a) as a method for enhancing the home of UCB HSC to the hematopoietic niche, b) UCB-derived Treg as a strategy to reduce or prevent acute GVHD, and c) CTN trials exporting the use of the double UCB platform in the context of non-myeloablative conditioning

Full bio

Frank Cichocki, PhD
Assistant Professor

612-626-8284
cich0040@umn.edu

Adaptive natural killer (NK) cell responses to viral infection and how these responses can be translated into novel therapies for hematopoietic stem cell transplantation recipients; NK cell signaling and primary immunodeficiences that impact NK cell function

Full bio

Sarah Cooley, MD
Associate Professor

612-625-8474
cool0023@umn.edu

Development of NK cell-based immunotherapies to treat leukemia and breast cancer

Full bio

Craig Eckfeldt, MD, PhD
Assistant Professor

612-626-6019
eckf0002@umn.edu

Understanding the role of RAS signaling pathways in acute myeloid leukemia (AML) to provide a foundation for the rational development of novel targeted therapies for human AML.

Full bio

Martin Felices, PhD
Assistant Professor

612-625-8942
mfelices@umn.edu

Natural killer (NK) cell biology, with a particular interest on NK cell education, signaling, and metabolism. The ultimate goal is to manipulate these pathways to enhance NK cell survival, expansion and anti-tumor function.

Full bio

Melissa Geller, MD, MS
Associate Professor

612-626-0665
gelle005@umn.edu

Ovarian cancer and the treatment of uterine sarcomas, identification early in the course of treatment of the alterations in biomarker and gene profiles that will predict response to chemotherapy

Full bio

Pankaj Gupta, MD
Professor

612-467-4135
gupta013@umn.edu

The role of proteoglycans in hematopoiesis and interactions between normal and leukemic stem cells with the microenvironment

Full bio

Keli Hippen, PhD
Assistant Professor

612-625-1430
hippe002@umn.edu

Translational development of nTreg and iTreg from adult peripheral blood and UCB, T progenitors from UCB and large scael manufacture of UCB CD19 T-CAR as a strategy for eradicating residual CD19 malignancies

Full bio

Shernan Holtan, MD
Assistant Professor

612-301-1095
sgholtan@umn.edu

Graft versus host disease; Immune reconstitution post-hematopoietic cell transplant; immune-based cancer therapies; melanoma

Full bio

Pamala Jacobson, PharmD, FCCP
Professor

612-624-6118
jacob117@umn.edu

Pharmacokinetics/pharacodynamics of chemotherapeutic and immunosuppressive agents for prevention of therapy-related complications

Full bio

L'Aurelle Johnson, PhD
Assistant Professor

612-624-5430
joh02745@umn.edu

Effects of chemotherapy in cancer patients and how responses differ depending on genetics and other factors

Full bio

Nobuaki J. Kikyo, MD, PhD
Associate Professor

612-624-0498
kikyo001@umn.edu

Mechanisms of nuclear reprogramming and how differentiated somatic nuclei are de-differentiated in egg cytoplasm and re-differentiated during subsequent embryogenesis

Full bio

Michael Kyba, PhD
Associate Professor

612-625-2173
kyba@umn.edu

The differentiation of embryonic and induced pluirpotential stem cells into muscle and hematopoietic stem cells

Full bio

Chap Le, PhD
Professor

612-624-9963
chap@umn.edu

Data-driven and include epidemiological methods, cross-over designs, survival analysis, ordered alternatives, ROC curves, and methods for the analysis of in vitro experiments—especially chemo-combination therapy

Full bio

Troy Lund, MD, PhD
Associate Professor

612-625-4185
lundx072@umn.edu

Understanding the pathophysiological processes underlying metabolic storages diseases (ALD, MLD, MPSI, ETC) and improving the outcomes for metabolic storage disease hematopoietic cell transplantation using the zebrafish model; hematopoietic cell engraftment process during bone marrow transplantation and improving the efficiency and time to engraftment

Full bio

Margaret MacMillan, MD
Professor

612-626-5768
macmi002@umn.edu

Prevention and treatment of acute GVHD; clincial trials using iTreg for prevention of acute GVHD in recipients of HLA-matched peripheral blood stem cells

Full bio

Brian McClune, DO
Assistant Professor

612-624-0123
bmcclune@umn.edu

Clinical trials in hematologic malignancy using stem cell transplantation

Full bio

Jeffrey McCullough, MD
Professor Emeritus

612-626-3272
mccul001@umn.edu

Transfusion medicine as it relates to cancer and HCT patients (e.g. leukocyte infusions in sepsis, platelet alloimmunization); development of novel therapies

Full bio

Philip McGlave, MD
Professor

612-624-0123
mcgla001@umn.edu

Treatment of malignant and nonmalignant hematologic disorders including aplastic anemia, leukemia, lymphoma, multiple myeloma, myelodysplasia, and blood and marrow transplantation; experimental therapy for malignant and non-malignant hematologic disorders including stem cell transplantation, immunotherapy, and gene transfer

Full bio

David McKenna, Jr, MD
Professor

612-624-5736
mcken020@umn.edu

Development of novel cellular therapies

Full bio

Jeffrey Miller, MD
Professor

612-625-7409
mille011@umn.edu

Development of immune-based therapeutics

Full bio

Weston Miller, MD
Assistant Professor

612-626-5768
mill4991@umn.edu

Development of novel clinical HCT trials in patients with metabolic disease; understanding the impact of high resolution HLA matching of UCB

Full bio

Paul Orchard, MD
Professor

612-626-2313
orcha001@umn.edu

Development of immune-based therapeutics

Full bio

Mark J. Osborn, PhD
Assistant Professor

612-625-8327
osbor026@umn.edu

Biology of homologous recombination as a strategy for gene transfer into HSC of patients with various genetic diseases, including Fanconi anemia

Full bio

Angela Panoskaltsis-Mortari, PhD
Professor

612-626-2950
panos001@umn.edu

The pathophysiology of acute lung injury in the setting of allogeneic HCT and GVHD and leads studies in pulmonary regenerative medicine

Full bio

Rita Perlingeiro, PhD
Professor

612-625-4984
perli032@umn.edu

Mechanisms underlying stem cell regulation and its relevance for tissue regneration and development of leukemia

Full bio

Arne Slungaard, MD
Professor

612-624-0123
slung001@umn.edu

Inflammatory mediators of coagulation and vascular integrity with direct relevance to tumor vascularity and thrombosis in patients with cancer

Full bio

Angela Smith, MD, MS
Assistant Professor

612-626-8094
smith719@umn.edu

Early and late effects of HCT, with a focus on venoocclusive disease of the liver and infertility

Full bio

Heather Stefanski, MD, PhD
Assistant Professor

612-625-4193
stef0030@umn.edu

Thymic epithelial cell protection and expansion of T progenitors (Tprog) extrapolated from the murine model

Full bio

Jakub Tolar, MD, PhD
Distinguished McKnight Professor

612-625-2912
tolar003@umn.edu

Development of non-hematopoietic stem cells for use in tissue repair particularly precancerous genetic diseases like epidermolysis bullosa, dykeratosis congentia and Fanconi anemia.

Full bio

Gregory Vercellotti, MD, FACP
Professor

612-624-0123
verce001@umn.edu

Inflammation, oxidative stress and endothelial integrity

Full bio

John E. Wagner, MD
Professor

612-626-2961
wagne002@umn.edu

Development of UCB as a source of hematopoietic and non-hematopoietic stem cells for treatment of malignancy; pathophysiology of Fanconi anemia and Epidermolysis bullosa predisposition to malignancy

Full bio

Erica Warlick, MD
Associate Professor

612-624-0123
ewarlick@umn.edu

The development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases

Full bio

Brenda Weigel, MD, MSc
Professor

612-626-5501
weige007@umn.edu

Testing new pharmacological and cellular therapeutic agents in preclinical mouse models and phase 1 testing in children

Full bio

Daniel Weisdorf, MD
Professor

612-624-3101
weisd001@umn.edu

Application of transplant therapy for acute leukemia as well as prevention and treatment of acute and chronic GVHD and late effects of HCT

Full bio

No Results